Allen Capital Group
ABBV icon

Allen Capital Group’s AbbVie ABBV Stock Holding History

Allen Capital Group’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.06M Buy
4,062
+147
+4% +$37.7K 0.09% 142
2026
Q2 		$985K Buy
3,915
+108
+3% +$23.2K 0.08% 145
2026
Q1 		$828K Buy
3,807
+409
+12% +$90.7K 0.07% 144
2025
Q4 		$776K Buy
3,398
+203
+6% +$46.2K 0.07% 151
2025
Q3 		$740K Sell
3,195
-22
-0.7% -$4.48K 0.07% 152
2025
Q2 		$597K Buy
3,217
+348
+12% +$64.7K 0.06% 164
2025
Q1 		$601K Buy
2,869
+91
+3% +$17.7K 0.07% 143
2024
Q4 		$494K Buy
2,778
+337
+14% +$62K 0.06% 152
2024
Q3 		$482K Buy
2,441
+279
+13% +$52.1K 0.06% 146
2024
Q2 		$371K Buy
2,162
+197
+10% +$32.6K 0.05% 149
2024
Q1 		$358K Buy
1,965
+361
+23% +$62.2K 0.05% 147
2023
Q4 		$249K Buy
+1,604
New +$234K 0.04% 157

Other funds holding ABBV

State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Allen Capital Group's ABBV Position: Q3 2026 in Review

Allen Capital Group increased its AbbVie (ABBV) stake by 3.8% in Q3 2026, buying an estimated $37.7K and bringing the position to 4,062 shares worth $1.06M. The position accounts for 0.09% of the portfolio, ranked #142.

Allen Capital Group first reported a position in ABBV in Q4 2023 and has held it in 12 quarters since. 3,546 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • Allen Capital Group held 4,062 shares of AbbVie worth $1.06M as of Q3 2026.
  • Allen Capital Group bought 147 AbbVie shares in Q3 2026, an estimated $37.7K.
  • AbbVie made up 0.09% of Allen Capital Group's portfolio in Q3 2026, its #142 holding.
  • Allen Capital Group first reported a position in AbbVie in Q4 2023 and has held it in 12 quarters since.
  • 3,546 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Allen Capital Group's 13F filing for Q3 2026, filed 27 Oct 2026.